Media
Media
Our latest announcements
Hansa Biopharma has carried out a directed cash share issue of approx. mSEK 232 and entered into binding agreement to restructure debt held by NovaQuest, including set-off issue of USD 14.9 million
Regulatory press release
19/06/2025
Hansa Biopharma intends to carry out directed share issue of approximately 10 million shares and has entered into non-binding terms with NovaQuest to restructure debt
Regulatory press release
18/06/2025
Hansa Biopharma to attend BIO International Convention
11/06/2025
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
09/06/2025
Media articles
Insights
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Addressing barriers to gene therapy treatment
31/01/2024
Patients' perspective
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patients' perspective
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
Global Corporate Affairs
Stephanie Kenney
Vice President Global Corporate Affairs
Email: [email protected]